IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
57.79
+0.61 (+1.08%)
As of 1:57PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close57.18
Open56.97
Bid57.830 x 800
Ask57.880 x 800
Day's Range56.63 - 57.92
52 Week Range39.07 - 59.81
Volume271,833
Avg. Volume988,604
Market Cap7.951B
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-0.506
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.54
Trade prices are not sourced from all markets
  • 4 Defensive Stocks to Buy Amid Shutdown and Brexit
    Zacksyesterday

    4 Defensive Stocks to Buy Amid Shutdown and Brexit

    Defensive equities could ride out market unpredictability.

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks2 days ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily3 days ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • 3 Top Biotech Stocks to Buy in January
    Motley Fool5 days ago

    3 Top Biotech Stocks to Buy in January

    Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    # Ionis Pharmaceuticals Inc ### NASDAQ/NGS:IONS View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate ## Bearish sentiment Short interest | Positive Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding IONS is favorable, with net inflows of $9.20 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
    Investor's Business Daily15 days ago

    Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018

    The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.

  • PR Newswire15 days ago

    Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

    CARLSBAD, Calif., Jan. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the Investors & Media section of the Company's website, www.ionispharma.com. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.

  • MoneyShow15 days ago

    Top Picks 2019- Ionis Pharmaceuticals IONS

    Ionis Pharmaceuticals (IONS) is my top pick as a conservative biotech recommendation in 2019; the company represents a unique blend with an exciting and broad pipeline of drug development candidates balanced by revenue generation from approved drugs, observes John McCamant, editor of The Medical Technology Stock Letter.

  • 4 of the Fastest Growing Biotech Stocks in 2019
    Motley Fool17 days ago

    4 of the Fastest Growing Biotech Stocks in 2019

    Earnings per share will more than double for each of these specialty drugmakers.

  • Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
    Market Realist21 days ago

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.

  • Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug
    Investor's Business Daily27 days ago

    Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug

    An experimental gene therapy from Novartis, called Zolgensma, is more cost effective than Biogen and Ionis Pharmaceuticals' treatment for a muscle-wasting disease, experts said this week.

  • MarketWatch28 days ago

    Ionis Pharmaceuticals outlines CEO succession plan

    Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. Shares of Ionis, which were flat after hours, had closed down 2.1% at $49.78 in regular trading Thursday.

  • PR Newswire28 days ago

    Ionis Announces Plans for Management Transitions in 2020

    CARLSBAD, Calif., Dec. 20, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) and its Board of Directors announced today that, effective January 2020, Ionis' founder and CEO, Stanley T. Crooke, M.D., Ph.D., will be transitioning from chief executive officer to executive chairman of Ionis' board of directors. As executive chairman, Dr. Crooke will continue to be responsible for the activities of the board and will remain active in the company, providing strategic advice and continuing to participate in the scientific activities of the company. The board has selected Brett P. Monia, Ph.D., who has been Ionis' chief operating officer for the last year and a member of the Ionis team since its founding nearly 30 years ago, to serve as Ionis' chief executive officer starting in January 2020.

  • GlobeNewswire28 days ago

    New Research: Key Drivers of Growth for Baxter International, Sempra Energy, Nielsen Holdings Plc, ARRIS International plc, Ionis Pharmaceuticals, and KB Home — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Dec. 20, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Do Analysts See Any Upside for Ionis Stock?
    Market Realistlast month

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”

  • Understanding Ionis Pharmaceuticals’ Operational Performance
    Market Realistlast month

    Understanding Ionis Pharmaceuticals’ Operational Performance

    In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.

  • Taking Stock of Ionis’s Performance
    Market Realistlast month

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.

  • Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?
    Insider Monkeylast month

    Should You Buy Ionis Pharmaceuticals, Inc. (IONS)?

    Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market […]

  • The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
    Zackslast month

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

    The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

  • Zackslast month

    Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

    A low key week for the biotech sector with focus on regular pipeline updates.

  • Simply Wall St.last month

    Is Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Expensive For A Reason? A Look At The Intrinsic Value

    I am going to run you through how I calculated the intrinsic value of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by estimating the company's future cash flows and discounting them to their Read More...

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONS

  • GlobeNewswirelast month

    Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

    Biogen Inc (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) announced today that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations. ALS with SOD1 mutations is a subtype of familial ALS and accounts for approximately two percent of all ALS cases.

  • Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
    Investor's Business Daily2 months ago

    Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis

    Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.